Raw Material Testing
Screening of high-risk inputs such as animal products and media.
What is RAW MATERIAL TESTING and why is it important?
The regulators require that the manufacturing process for all biologics be rigorously defined and strictly controlled. Clearly this begins with defining and controlling the input and in-process raw materials.
The input raw materials for a cell based manufacturing process will include the cell media and any salts, buffers and other nutrients which are required for the manufacturing cells to grow and produce the biologic. While common in a research setting, the use of animal derived materials has long been known to be of specific concern for GMP manufacturing. For example, non-irradiated bovine serum is known to present significant risk of containing high levels of live virus. Indeed, animal derived enzymes such as porcine trypsin carry similar viral risks to serum. Due to these significant risks, manufacturers have tried to remove the highest risk raw materials such as serum and trypsin from their manufacturing processes.
Unfortunately it is not always possible to remove animal derived material from the manufacturing process. Apart from a number of clinical materials directly uses animal donor materials such as bone or skin; some cell based manufacturing processes may not be able to eliminate animal serum or other materials as these are critical to production. In such cases treatment of the high risk material for viral reduction/removal is desirable, but unfortunately is not always possible. For example, irradiation is highly effective at inactivating live virus contamination. However, it can also damage key components within the serum which are essential for the manufacturing process. In these cases this animal derived raw material must be screened to ensure that there are no significant viral risks.
Even in animal free manufacturing processes there is still the risk of raw materials being contaminated through environmental sources. For example, minute virus of mice (MVM or MMV) is endemic to wild mice and is shed through their feces in very high quantities. MMV has been demonstrated as the main cause of viral contamination in mAb production as it can infect and replicate in CHO cells. It is therefore easy to see how this virus can enter into the manufacturing process through poor warehousing and control of the raw materials.
Raw materials are most often screened for viral contamination using molecular detection, specifically PCR, as it is highly sensitive and rapid. The issue with PCR is that it cannot discriminate between live-replicating virus and virus which has been inactivated through, for example irradiation. PCR would therefore identify serum as containing virus even through it was fully inactivated, presenting no risk. More traditional cell-based methods can be used, but these can take weeks. Cell-based methods also run the risk of being permissible to infection without showing any cytopathic or histochemical indications.
NGS can detect viral replication, for example as specific incorporation events into the viral genome. Using this technique it is therefore possible to discriminate between inactivated virus and virus which is capable of replication. This may prove advantageous to manufacturers who cannot use traditional methods to screen their raw materials.
What we do
- mAbs and recombinant biologics
- Viral vectors
- Cell therapies
- Vaccines
- RNA based therapeutics
- Cultured meat
- Other clinical applications
Benefits of NGS for raw material testing
✓
GMP validated
✓
Fast results – days vs weeks for cell based methods
✓
Discrimination of live versus inactivated virus
✓
Specific identification of contamination

SAMPLE REQUIREMENTS
The sample requirements for raw material testing will depend on the materials being tested and the approach taken. Please discuss with our PathoQuest experts who will be able to advise you.
Challenges solved
- Samples which may be difficult to test with traditional cell-based methods
- False positives from PCR detection of inactivated virus
- Identification of known and unknown contaminants instructing mitigation strategies
- Allowing manufacturing to start faster.
OTHER SERVICES
Adventitious Virus Testing
Detection of viral contamination within the manufacturing process and beyond.
READ MORE

nCats Integration Site Analysis
Characterisation of genetic modifications for clone selection, genetic stability and lot release
Identity Confirmation
Genetic characterization of viral and plasmid products for release.
READ MORE
In Vivo Replacement
NGS as an ethical alternative to animals in biosafety testing and characterization.
READ MORE
Cell Line Characterization
Biosafety screening and stability testing of manufacturing cells.
READ MORE
HLA Genotyping
Characterizing and screening for novel and emerging cell therapies.
READ MORE
Contact us
U.S.
466 Devon Park Dr
Wayne, PA 19087
United States
E: contact@pathoquest.com
Sign up for our latest news
France
+33 (0)1 70 82 17 90
Biopark -Bâtiment B,
11, rue Watt
75013 Paris, France
How can PathoQuest help?
U.S.
466 Devon Park Dr
Wayne, PA 19087
United States
France
+33 (0)1 70 82 17 90
Biopark -Bâtiment B,
11, rue Watt
75013 Paris, France
E: contact@pathoquest.com
How can PathoQuest help?
Sign up for our latest news